Oligomenorrhea treatment by purified FSH using a fixed protocol

Area of Science:

• Reproductive Endocrinology
• Gynecology
• Clinical Pharmacology

Background:

• Oligomenorrhea, characterized by infrequent menstrual periods, affects reproductive health in women of reproductive age.
• Current treatments for anovulation often involve higher doses of gonadotropins, potentially leading to side effects and increased costs.
• Evaluating lower-dose, fixed-protocol regimens is crucial for optimizing therapeutic strategies in reproductive medicine.

Purpose of the Study:

• To assess the efficacy of a low-dose, fixed-protocol administration of purified follicle-stimulating hormone (FSH) in inducing ovulation and menstruation.
• To evaluate the safety and tolerability profile of this low-dose FSH regimen in women with oligomenorrhea not seeking pregnancy.
• To establish a potentially more accessible and tolerable treatment option for menstrual cycle regulation.

Main Methods:

• A prospective study involving 10 oligomenorrheic patients (aged 18-30) not desiring pregnancy.
• Administration of a low dose (75 IU/day for 5 days) of purified FSH (Metrodin) over 25 treatment cycles.
• Monitoring for the onset of menstruation and verification of ovulation through clinical and laboratory assessments.

Main Results:

• Menstruation onset was observed in 70% of patients (7 out of 10).
• Ovulation was verified in 52% of treatment cycles (13 out of 25) across 50% of the patients.
• The treatment was well-tolerated, with no reported side effects; one patient experienced spotting, and two showed no response.

Conclusions:

• Low-dose purified FSH administered via a fixed protocol is effective in inducing ovulation and menstruation in a significant proportion of oligomenorrheic patients.
• The regimen exhibits a favorable safety and tolerability profile, suggesting it as a viable therapeutic option.
• Further research may explore optimizing this low-dose approach for improved outcomes in managing menstrual irregularities.